Table 3. Efficacy of anti-EGFR antibody treatment according to the RAS/BRAF mutational status.
|
RAS/BRAF
wild |
RAS
mut |
BRAFV600E
mut |
BRAFnon-V600E
mut |
|||||
|---|---|---|---|---|---|---|---|---|
| (n=94) | (n=40) | (n=9) | (n=7) | |||||
|
PFS, months | ||||||||
| Median | 5.9 | 2.1 | 1.6 | 2.4 | ||||
| 95% CI | 4.9–7.7 |
1.9–2.6 |
1.1–3.4 |
2.1–4.0 |
||||
|
OS, months | ||||||||
| Median | 14.5 | 6.3 | 4.6 | 8.1 | ||||
| 95% CI | 12.6–16.2 |
4.6–8.4 |
1.3–21.2 |
5.3–16.9 |
||||
|
RR, % | ||||||||
| 31.9 | 2.5 | 0 | 0 | |||||
| 95% CI | 22.7–42.3 |
0.1–13.2 |
0.0–33.6 |
0.0–41.0 |
||||
|
Response, No, % | ||||||||
| CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR | 30 | 31.9 | 1 | 2.5 | 0 | 0 | 0 | 0 |
| Long SD >6 months | 45 | 47.9 | 3 | 7.5 | 1 | 11.1 | 1 | 14.3 |
Abbreviations: CR=complete response; DCR=disease control rate; mut=mutant; NE=not evaluable; PD=progressive disease; PR=partial response; SD=stable disease; wild=wild-type.
Wild-type RAS/BRAF was defined as all wild-type sequences with RAS, BRAFV600E, and BRAFnon-V600E.